Direct oral anticoagulants (DOAC) are widely used for prevention of stroke in patients with atrial fibrillation. The need for therapeutic drug monitoring of DOACs remains unclear. Measurement of anti-Xa activity that directly correlates with serum drug concentration seems to be a promising approach for monitoring of Xa inhibitors.
No takes yet. Share an insight, caveat, or question.
Kochetkova et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: